Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: Adefovir versus entecavir

Jung Min Lee, Hyung Joon Kim, Jun Yong Park, Chun Kyon Lee, Do Young Kim, Ja Kyung Kim, Hyun Woong Lee, Yong Han Paik, Kwan Sik Lee, Kwang Hyub Han, Chae Yoon Chon, Sun Pyo Hong, Tin Nguyen, Sang Hoon Ahn

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB). We compared the efficacy of ADV and ETV rescue monotherapy in HBeAg-positive patients with confirmed genotypic 3TC resistance. Methods: A total of 160 HBeAg-positive patients with confirmed 3TC resistance underwent switch therapy (91 ADV and 59 ETV). Parameters assessed included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower detection limit <300 copies/ml), virological breakthrough and initial virological response (IVR) at 3 (IVR-3) and 6 (IVR-6) months. Results: Following 52 weeks of treatment in the ADV and ETV groups, serum HBV DNA became undetectable in 25 (27.5%) and 21 (35.6%; P=0.292) patients, ALT normalization occurred in 67/78 (85.9%) and 43/47 (91.5%; P=0.351). HBeAg seroconversion in 4 (4.4%) and 1 (1.7%; P=1.000), IVR-3 in 19 (20.9%) and 18 (30.5%). IVR-6 in 40 (44.0%) and 25 (42.4%) and virological breakthrough in 2 (2.2%) and 1 (1.7%; P=1.000) patients, respectively. Conclusions: ADV and ETV revealed comparable efficacy after 52 weeks of treatment in HBeAg-positive patients with 3TC resistance. Undetectable HBV DNA in serum following 52 weeks of treatment was predictable with IVR-3 and IVR-6 in both groups.

Original languageEnglish
Pages (from-to)705-712
Number of pages8
JournalAntiviral Therapy
Volume14
Issue number5
Publication statusPublished - 2009 Sep 10

Fingerprint

Lamivudine
Hepatitis B e Antigens
Chronic Hepatitis B
Hepatitis B virus
Alanine Transaminase
DNA
Serum
Therapeutics
Limit of Detection
entecavir
adefovir
adefovir dipivoxil
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Lee, Jung Min ; Kim, Hyung Joon ; Park, Jun Yong ; Lee, Chun Kyon ; Kim, Do Young ; Kim, Ja Kyung ; Lee, Hyun Woong ; Paik, Yong Han ; Lee, Kwan Sik ; Han, Kwang Hyub ; Chon, Chae Yoon ; Hong, Sun Pyo ; Nguyen, Tin ; Ahn, Sang Hoon. / Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B : Adefovir versus entecavir. In: Antiviral Therapy. 2009 ; Vol. 14, No. 5. pp. 705-712.
@article{76947ad6674b49fc8455b22efeb75b45,
title = "Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: Adefovir versus entecavir",
abstract = "Background: The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB). We compared the efficacy of ADV and ETV rescue monotherapy in HBeAg-positive patients with confirmed genotypic 3TC resistance. Methods: A total of 160 HBeAg-positive patients with confirmed 3TC resistance underwent switch therapy (91 ADV and 59 ETV). Parameters assessed included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower detection limit <300 copies/ml), virological breakthrough and initial virological response (IVR) at 3 (IVR-3) and 6 (IVR-6) months. Results: Following 52 weeks of treatment in the ADV and ETV groups, serum HBV DNA became undetectable in 25 (27.5{\%}) and 21 (35.6{\%}; P=0.292) patients, ALT normalization occurred in 67/78 (85.9{\%}) and 43/47 (91.5{\%}; P=0.351). HBeAg seroconversion in 4 (4.4{\%}) and 1 (1.7{\%}; P=1.000), IVR-3 in 19 (20.9{\%}) and 18 (30.5{\%}). IVR-6 in 40 (44.0{\%}) and 25 (42.4{\%}) and virological breakthrough in 2 (2.2{\%}) and 1 (1.7{\%}; P=1.000) patients, respectively. Conclusions: ADV and ETV revealed comparable efficacy after 52 weeks of treatment in HBeAg-positive patients with 3TC resistance. Undetectable HBV DNA in serum following 52 weeks of treatment was predictable with IVR-3 and IVR-6 in both groups.",
author = "Lee, {Jung Min} and Kim, {Hyung Joon} and Park, {Jun Yong} and Lee, {Chun Kyon} and Kim, {Do Young} and Kim, {Ja Kyung} and Lee, {Hyun Woong} and Paik, {Yong Han} and Lee, {Kwan Sik} and Han, {Kwang Hyub} and Chon, {Chae Yoon} and Hong, {Sun Pyo} and Tin Nguyen and Ahn, {Sang Hoon}",
year = "2009",
month = "9",
day = "10",
language = "English",
volume = "14",
pages = "705--712",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "5",

}

Lee, JM, Kim, HJ, Park, JY, Lee, CK, Kim, DY, Kim, JK, Lee, HW, Paik, YH, Lee, KS, Han, KH, Chon, CY, Hong, SP, Nguyen, T & Ahn, SH 2009, 'Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: Adefovir versus entecavir', Antiviral Therapy, vol. 14, no. 5, pp. 705-712.

Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B : Adefovir versus entecavir. / Lee, Jung Min; Kim, Hyung Joon; Park, Jun Yong; Lee, Chun Kyon; Kim, Do Young; Kim, Ja Kyung; Lee, Hyun Woong; Paik, Yong Han; Lee, Kwan Sik; Han, Kwang Hyub; Chon, Chae Yoon; Hong, Sun Pyo; Nguyen, Tin; Ahn, Sang Hoon.

In: Antiviral Therapy, Vol. 14, No. 5, 10.09.2009, p. 705-712.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B

T2 - Adefovir versus entecavir

AU - Lee, Jung Min

AU - Kim, Hyung Joon

AU - Park, Jun Yong

AU - Lee, Chun Kyon

AU - Kim, Do Young

AU - Kim, Ja Kyung

AU - Lee, Hyun Woong

AU - Paik, Yong Han

AU - Lee, Kwan Sik

AU - Han, Kwang Hyub

AU - Chon, Chae Yoon

AU - Hong, Sun Pyo

AU - Nguyen, Tin

AU - Ahn, Sang Hoon

PY - 2009/9/10

Y1 - 2009/9/10

N2 - Background: The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB). We compared the efficacy of ADV and ETV rescue monotherapy in HBeAg-positive patients with confirmed genotypic 3TC resistance. Methods: A total of 160 HBeAg-positive patients with confirmed 3TC resistance underwent switch therapy (91 ADV and 59 ETV). Parameters assessed included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower detection limit <300 copies/ml), virological breakthrough and initial virological response (IVR) at 3 (IVR-3) and 6 (IVR-6) months. Results: Following 52 weeks of treatment in the ADV and ETV groups, serum HBV DNA became undetectable in 25 (27.5%) and 21 (35.6%; P=0.292) patients, ALT normalization occurred in 67/78 (85.9%) and 43/47 (91.5%; P=0.351). HBeAg seroconversion in 4 (4.4%) and 1 (1.7%; P=1.000), IVR-3 in 19 (20.9%) and 18 (30.5%). IVR-6 in 40 (44.0%) and 25 (42.4%) and virological breakthrough in 2 (2.2%) and 1 (1.7%; P=1.000) patients, respectively. Conclusions: ADV and ETV revealed comparable efficacy after 52 weeks of treatment in HBeAg-positive patients with 3TC resistance. Undetectable HBV DNA in serum following 52 weeks of treatment was predictable with IVR-3 and IVR-6 in both groups.

AB - Background: The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB). We compared the efficacy of ADV and ETV rescue monotherapy in HBeAg-positive patients with confirmed genotypic 3TC resistance. Methods: A total of 160 HBeAg-positive patients with confirmed 3TC resistance underwent switch therapy (91 ADV and 59 ETV). Parameters assessed included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower detection limit <300 copies/ml), virological breakthrough and initial virological response (IVR) at 3 (IVR-3) and 6 (IVR-6) months. Results: Following 52 weeks of treatment in the ADV and ETV groups, serum HBV DNA became undetectable in 25 (27.5%) and 21 (35.6%; P=0.292) patients, ALT normalization occurred in 67/78 (85.9%) and 43/47 (91.5%; P=0.351). HBeAg seroconversion in 4 (4.4%) and 1 (1.7%; P=1.000), IVR-3 in 19 (20.9%) and 18 (30.5%). IVR-6 in 40 (44.0%) and 25 (42.4%) and virological breakthrough in 2 (2.2%) and 1 (1.7%; P=1.000) patients, respectively. Conclusions: ADV and ETV revealed comparable efficacy after 52 weeks of treatment in HBeAg-positive patients with 3TC resistance. Undetectable HBV DNA in serum following 52 weeks of treatment was predictable with IVR-3 and IVR-6 in both groups.

UR - http://www.scopus.com/inward/record.url?scp=69849090825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69849090825&partnerID=8YFLogxK

M3 - Article

C2 - 19704174

AN - SCOPUS:69849090825

VL - 14

SP - 705

EP - 712

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 5

ER -